Kappa opioid receptor antagonists to treat depression, anxiety
Novel KOR antagonists can be developed as a therapeutic treatment for mental conditions such as depression and anxiety related disorders.KOR is localized in the central and peripheral nervous system and its activation has been linked to antinociception, dysphoria and anxiety. As a result, KOR may be a potential target for drug discovery. The current invention has developed a novel class of compounds capable of antagonizing KOR. These novel compounds have superior biological potency and pharmacological activity relative to KOR antagonists that are currently on the market.